{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:10:38Z","timestamp":1765807838580},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,26]]},"DOI":"10.7759\/cureus.11173","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T15:37:27Z","timestamp":1603726647000},"source":"Crossref","is-referenced-by-count":5,"title":["Cardiovascular Involvement in Psoriasis, Diagnosing Subclinical Atherosclerosis, Effects of Biological and Non-Biological Therapy: A Literature Review"],"prefix":"10.7759","author":[{"given":"Sharathshiva","family":"Valaiyaduppu Subas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinayak","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal","family":"Busa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishan","family":"Antony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suganya","family":"Marudhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauli","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Cancarevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Health Organization. Cardiovascular diseases (CVDs). (2017). Accessed: May 17, 2017: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics-2019 update: a report from the American Heart Association","volume":"139","author":"Benjamin EJ","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A, et al.. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019, 139:e56-e528. 10.1161\/CIR.0000000000000659","journal-title":"Circulation"},{"key":"ref3","article-title":"Deaths: Leading Causes for 2017. National Vital Statistics Reports","author":"Heron M","year":"2017","unstructured":"Heron M. Deaths: Leading Causes for 2017. National Vital Statistics Reports. Sudol J (ed): National Center for Health Statistics, Hyattsville, MD; 2017."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2014an inflammatory disease","volume":"340","author":"Ross R","year":"1999","unstructured":"Ross R. Atherosclerosis\u2014an inflammatory disease. N Engl J Med. 1999, 340:115-126. 10.1056\/NEJM199901143400207","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nri2415","article-title":"The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models","volume":"8","author":"Weber C","year":"2008","unstructured":"Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol. 2008, 8:802-815. 10.1038\/nri2415","journal-title":"Nat Rev Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nri1882","article-title":"The immune response in atherosclerosis: a double-edged sword","volume":"6","author":"Hansson GK","year":"2006","unstructured":"Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006, 6:508-519. 10.1038\/nri1882","journal-title":"Nat Rev Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2019.10.007","article-title":"Coronary artery calcium scoring for individualized cardiovascular risk estimation in important patient subpopulations after the 2019 AHA\/ACC primary prevention guidelines","volume":"62","author":"Dzaye O","year":"2019","unstructured":"Dzaye O, Dudum R, Reiter-Brennan C, Kianoush S, Tota-Maharaj R, Cainzos-Achirica M, Blaha MJ. Coronary artery calcium scoring for individualized cardiovascular risk estimation in important patient subpopulations after the 2019 AHA\/ACC primary prevention guidelines. Prog Cardiovasc Dis. 2019, 62:423-430. 10.1016\/j.pcad.2019.10.007","journal-title":"Prog Cardiovasc Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.2.239","article-title":"National psoriasis foundation clinical consensus on disease severity","volume":"143","author":"Pariser DM","year":"2007","unstructured":"Pariser DM, Bagel J, Gelfand JM, et al.. National psoriasis foundation clinical consensus on disease severity. Arch Dermatol. 2007, 143:239-242. 10.1001\/archderm.143.2.239","journal-title":"Arch Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database","volume":"31","author":"Mehta NN","year":"2010","unstructured":"Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database. Eur Heart J. 2010, 31:1000-1006. 10.1093\/eurheartj\/ehp567","journal-title":"Eur Heart J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand JM","year":"2006","unstructured":"Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006, 296:1735-1741. 10.1001\/jama.296.14.1735","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.09020.x","article-title":"Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis","volume":"160","author":"Brauchli YB","year":"2009","unstructured":"Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol. 2009, 160:1048-1056. 10.1111\/j.1365-2133.2008.09020.x","journal-title":"Br J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/08830185.2018.1539084","article-title":"Psoriasis and cardiovascular disease: the elusive link","volume":"38","author":"Manolis AA","year":"2019","unstructured":"Manolis AA, Manolis TA, Melita H, Manolis AS. Psoriasis and cardiovascular disease: the elusive link. Int Rev Immunol. 2019, 38:33-54. 10.1080\/08830185.2018.1539084","journal-title":"Int Rev Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12673","article-title":"Are all patients with psoriasis at increased risk for coronary artery disease?","volume":"54","author":"Seremet S","year":"2015","unstructured":"Seremet S, Genc B, Tastan A, et al.. Are all patients with psoriasis at increased risk for coronary artery disease?. Int J Dermatol. 2015, 54:355-361. 10.1111\/ijd.12673","journal-title":"Int J Dermatol"},{"key":"ref14","article-title":"Psoriasis and coronary artery disease in Hispanics","volume":"108","author":"Nieves-Rivera J","year":"2016","unstructured":"Nieves-Rivera J, Sulia C, Gonzalez R, Figueroa L, Banchs H, Altieri P, Gonz\u00e1lez W. Psoriasis and coronary artery disease in Hispanics. Bol Asoc Med P R. 2016, 108:65-67.","journal-title":"Bol Asoc Med P R"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.03.028","article-title":"Attributable risk estimate of severe psoriasis on major cardiovascular events","volume":"124","author":"Mehta NN","year":"2011","unstructured":"Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, Gelfand JM. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011, 124:775.E1-775.E6. 10.1016\/j.amjmed.2011.03.028","journal-title":"Am J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08780.x","article-title":"Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach","volume":"159","author":"Spah F","year":"2008","unstructured":"Spah F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol. 2008, 159:10-17. 10.1111\/j.1365-2133.2008.08780.x","journal-title":"Br J Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.08.011","article-title":"The cytokine and chemokine network in psoriasis","volume":"25","author":"Nickoloff BJ","year":"2007","unstructured":"Nickoloff BJ, Xin H, Nestle FO, Qin JZ. The cytokine and chemokine network in psoriasis. Clin Dermatol. 2007, 25:568-573. 10.1016\/j.clindermatol.2007.08.011","journal-title":"Clin Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs399","article-title":"Interleukin-17 in atherosclerosis and cardiovascular disease: the good, the bad, and the unknown","volume":"34","author":"Liuzzo G","year":"2013","unstructured":"Liuzzo G, Trotta F, Pedicino D. Interleukin-17 in atherosclerosis and cardiovascular disease: the good, the bad, and the unknown. Eur Heart J. 2013, 34:556-559. 10.1093\/eurheartj\/ehs399","journal-title":"Eur Heart J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.10.092","article-title":"Ischemic cardiovascular involvement in psoriasis: a systematic review","volume":"178","author":"Mosca S","year":"2015","unstructured":"Mosca S, Gargiulo P, Balato N, et al.. Ischemic cardiovascular involvement in psoriasis: a systematic review. Int J Cardiol. 2015, 178:191-199. 10.1016\/j.ijcard.2014.10.092","journal-title":"Int J Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby P","year":"2002","unstructured":"Libby P. Inflammation in atherosclerosis. Nature. 2002, 420:868-874. 10.1038\/nature01323","journal-title":"Nature"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09281.x","article-title":"More than skin deep: atherosclerosis as a systemic manifestation of psoriasis","volume":"161","author":"Alexandroff AB","year":"2009","unstructured":"Alexandroff AB, Pauriah M, Camp RD, Lang CC, Struthers AD, Armstrong DJ. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol. 2009, 161:1-7. 10.1111\/j.1365-2133.2009.09281.x","journal-title":"Br J Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21782","article-title":"Association of systemic lupus erythematosus with angiographically-defined coronary artery disease: a retrospective cohort study","volume":"65","author":"Kaul MS","year":"2013","unstructured":"Kaul MS, Rao SV, Shaw LK, Honeycutt E, Ardoin SP, St Clair EW. Association of systemic lupus erythematosus with angiographically-defined coronary artery disease: a retrospective cohort study. Arthritis Care Res. 2013, 65:266-273. 10.1002\/acr.21782","journal-title":"Arthritis Care Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07562.x","article-title":"Psoriasis: a possible risk factor for development of coronary artery calcification","volume":"156","author":"Ludwig RJ","year":"2007","unstructured":"Ludwig RJ, Herzog C, Rostock A, et al.. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007, 156:271-276. 10.1111\/j.1365-2133.2006.07562.x","journal-title":"Br J Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.026859","article-title":"Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study","volume":"136","author":"Lerman JB","year":"2017","unstructured":"Lerman JB, Joshi AA, Chaturvedi A, et al.. Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study. Circulation. 2017, 136:263-276. 10.1161\/CIRCULATIONAHA.116.026859","journal-title":"Circulation"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02936.x","article-title":"Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis","volume":"23","author":"Balci DD","year":"2009","unstructured":"Balci DD, Balci A, Karazincir S, et al.. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol. 2009, 23:1-6. 10.1111\/j.1468-3083.2008.02936.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.118.313608","article-title":"Association between oxidation-modified lipoproteins and coronary plaque in psoriasis: an observational cohort study","volume":"123","author":"Sorokin AV","year":"2018","unstructured":"Sorokin AV, Kotani K, Elnabawi YA, et al.. Association between oxidation-modified lipoproteins and coronary plaque in psoriasis: an observational cohort study. Circ Res. 2018, 123:1244-1254. 10.1161\/CIRCRESAHA.118.313608","journal-title":"Circ Res"},{"key":"ref27","article-title":"Psoriasis and cardiovascular risk factors: increased serum myeloperoxidase and corresponding immunocellular overexpression by Cd11b+ CD68+ macrophages in skin lesions","volume":"6","author":"Cao LY","year":"2014","unstructured":"Cao LY, Soler DC, Debanne SM, et al.. Psoriasis and cardiovascular risk factors: increased serum myeloperoxidase and corresponding immunocellular overexpression by Cd11b+ CD68+ macrophages in skin lesions. Am J Transl Res. 2014, 6:16-27.","journal-title":"Am J Transl Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.309637","article-title":"GlycA is a novel biomarker of inflammation and subclinical cardiovascular disease in psoriasis","volume":"119","author":"Joshi AA","year":"2016","unstructured":"Joshi AA, Lerman JB, Aberra TM, et al.. GlycA is a novel biomarker of inflammation and subclinical cardiovascular disease in psoriasis. Circ Res. 2016, 119:1242-1253. 10.1161\/CIRCRESAHA.116.309637","journal-title":"Circ Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv339","article-title":"Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis","volume":"36","author":"Salahuddin T","year":"2015","unstructured":"Salahuddin T, Natarajan B, Playford MP, et al.. Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis. Eur Heart J. 2015, 36:2662-2665. 10.1093\/eurheartj\/ehv339","journal-title":"Eur Heart J"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.5543\/tkda.2014.78949","article-title":"Epicardial fat thickness in patients with psoriasis vulgaris","volume":"42","author":"Bacaks\u0131z A","year":"2014","unstructured":"Bacaks\u0131z A, Tasal A, Sevgili E, Erdo\u011fan E, Onsun N. Epicardial fat thickness in patients with psoriasis vulgaris. Arch Turk Soc Cardiol. 2014, 42:47-54. 10.5543\/tkda.2014.78949","journal-title":"Arch Turk Soc Cardiol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2017.07.010","article-title":"Monitoring urinary orosomucoid in patients undergoing cardiac surgery: a promising novel inflammatory marker","volume":"50","author":"Kust\u00e1n P","year":"2017","unstructured":"Kust\u00e1n P, Szirmay B, K\u0151szegi T, et al.. Monitoring urinary orosomucoid in patients undergoing cardiac surgery: a promising novel inflammatory marker. Clin Biochem. 2017, 50:1002-1006. 10.1016\/j.clinbiochem.2017.07.010","journal-title":"Clin Biochem"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S197633","article-title":"Urinary orosomucoid: a new marker of cardiovascular risk in psoriatic patients?","volume":"15","author":"N\u00e9meth B","year":"2019","unstructured":"N\u00e9meth B, P\u00e9ter I, Boncz I, et al.. Urinary orosomucoid: a new marker of cardiovascular risk in psoriatic patients?. Ther Clin Risk Manag. 2019, 15:831-837. 10.2147\/TCRM.S197633","journal-title":"Ther Clin Risk Manag"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2016.05.019","article-title":"Cardiogoniometry in psoriatic patients and its comparison with a control group","volume":"69","author":"Poorzand H","year":"2017","unstructured":"Poorzand H, Kiafar B, Heravi FA, et al.. Cardiogoniometry in psoriatic patients and its comparison with a control group. Indian Heart J. 2017, 69:75-80. 10.1016\/j.ihj.2016.05.019","journal-title":"Indian Heart J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.05.040","article-title":"Efficacy of simvastatin in plaque psoriasis: a pilot study","volume":"57","author":"Shirinsky IV","year":"2007","unstructured":"Shirinsky IV, Shirinsky VS. Efficacy of simvastatin in plaque psoriasis: a pilot study. J Am Acad Dermatol. 2007, 57:529-531. 10.1016\/j.jaad.2007.05.040","journal-title":"J Am Acad Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04450.x","article-title":"Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian psocare registry","volume":"27","author":"Gisondi P","year":"2013","unstructured":"Gisondi P, Cazzaniga S, Chimenti S, et al.. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian psocare registry. J Eur Acad Dermatol Venereol. 2013, 27:30-41. 10.1111\/j.1468-3083.2012.04450.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-872398","article-title":"Effect of drugs on homocysteine concentrations","volume":"5","author":"Dierkes J","year":"2005","unstructured":"Dierkes J, Westphal S. Effect of drugs on homocysteine concentrations. Semin Vasc Med. 2005, 5:124-139. 10.1055\/s-2005-872398","journal-title":"Semin Vasc Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.06.017","article-title":"Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis","volume":"52","author":"Prodanovich S","year":"2005","unstructured":"Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005, 52:262-267. 10.1016\/j.jaad.2004.06.017","journal-title":"J Am Acad Dermatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.101.18.2149","article-title":"Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction","volume":"101","author":"Ridker PM","year":"2000","unstructured":"Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000, 101:2149-2153. 10.1161\/01.cir.101.18.2149","journal-title":"Circulation"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.110.214585","article-title":"Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-\u03b1 blockers and traditional disease-modifying antirheumatic drugs","volume":"31","author":"Di Minno MN","year":"2011","unstructured":"Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-\u03b1 blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol. 2011, 31:705-712. 10.1161\/ATVBAHA.110.214585","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.06.112","article-title":"Anti-tumor necrosis factor alpha treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis","volume":"151","author":"Avgerinou G","year":"2011","unstructured":"Avgerinou G, Tousoulis D, Siasos G, et al.. Anti-tumor necrosis factor alpha treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis. Int J Cardiol. 2011, 151:382-383. 10.1016\/j.ijcard.2011.06.112","journal-title":"Int J Cardiol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.2502","article-title":"Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis","volume":"148","author":"Wu JJ","year":"2012","unstructured":"Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012, 148:1244-1250. 10.1001\/archdermatol.2012.2502","journal-title":"Arch Dermatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001538","article-title":"Cutting edge: a critical functional role for IL-23 in psoriasis","volume":"185","author":"Tonel G","year":"2010","unstructured":"Tonel G, Conrad C, Laggner U, et al.. Cutting edge: a critical functional role for IL-23 in psoriasis. J Immunol. 2010, 185:5688-5691. 10.4049\/jimmunol.1001538","journal-title":"J Immunol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04705.x","article-title":"Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12\/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis","volume":"27","author":"Langley RG","year":"2013","unstructured":"Langley RG, Papp K, Gottlieb AB, et al.. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12\/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2013, 27:1252-1261. 10.1111\/j.1468-3083.2012.04705.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1211","article-title":"Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials","volume":"306","author":"Ryan C","year":"2011","unstructured":"Ryan C, Leonardi CL, Krueger JG, et al.. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011, 306:864-871. 10.1001\/jama.2011.1211","journal-title":"JAMA"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.114.303567","article-title":"IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles","volume":"35","author":"Taleb S","year":"2015","unstructured":"Taleb S, Tedgui A, Mallat Z. IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles. Arterioscler Thromb Vasc Biol. 2015, 35:258-264. 10.1161\/ATVBAHA.114.303567","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.111.229997","article-title":"Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice","volume":"32","author":"Danzaki K","year":"2012","unstructured":"Danzaki K, Matsui Y, Ikesue M, et al.. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2012, 32:273-280. 10.1161\/ATVBAHA.111.229997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006133","article-title":"Transforming growth factor-\u03b2 signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway","volume":"5","author":"Gistera A","year":"2013","unstructured":"Gistera A, Robertson AK, Andersson J, et al.. Transforming growth factor-\u03b2 signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway. Sci Transl Med. 2013, 5:196ra100. 10.1126\/scitranslmed.3006133","journal-title":"Sci Transl Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease PJ","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, et al.. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015, 373:1329-1339. 10.1056\/NEJMoa1412679","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/41829-cardiovascular-involvement-in-psoriasis-diagnosing-subclinical-atherosclerosis-effects-of-biological-and-non-biological-therapy-a-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:19:24Z","timestamp":1707506364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/41829-cardiovascular-involvement-in-psoriasis-diagnosing-subclinical-atherosclerosis-effects-of-biological-and-non-biological-therapy-a-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,26]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.11173","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,26]]}}}